BridgeBio Pharma Inc. (BBIO) Announces $250 Million Private Placement Equity Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
September 25, 2023 7:30 AM EDT- $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US
- BridgeBio anticipates this raise, coupled with several less dilutive financings available to the Company, fully capitalizes the Company to profitability
PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has entered into a securities purchase agreement with certain existing and... More
